WHO chief warns towards ‘vaccine nationalism’ – Home Health Choices
Berlin: The head of the World Health Organization (WHO) on…Latest Updates
A workforce of researchers on the Indraprastha Institute of Information Technology (IIIT) Delhi comprising Angshul Majumdar, professor within the Department of Electronics and Communication Engineering and PhD scholar Aanchal Mongia has labored on an AI-based computational mannequin for drug repurposing within the therapy of COVID-19.
How does it work
“The AI model looks at the database of all antivirals that have been used for curing virus-borne diseases such as dengue, chikunguniya etc and also at the chemical structure of viruses that are similar to the coronavirus. Based on the similarities, the AI model recommends existing antivirals that may be useful in treating COVID-19,” says Majumdar. The workforce’s AI mannequin has been developed in collaboration with Dr Sanjay Kumar Saha of IPGME&R, Kolkata, and Emilie Chouzenoux, researcher at INRIA, Saclay, Paris, France, who’ve helped in deriving the AI algorithm and sharing their medical insights.
Why not a vaccine
While trials are on to discover a vaccine for stopping the coronavirus infection, it could nonetheless take a yr or two for the vaccine to be out there for mass use. “This makes repurposing of existing drugs the best means to address COVID-19. Using clinical expertise, one would ideally need to try out 100+ existing antivirals from the database of drugs which would be both time consuming and a drain on resources. Our AI model will help clinicians in selecting a few antivirals that have better chances of succeeding,” says Aanchal.
So far, the AI mannequin has chosen medicine equivalent to Remdesivir, Umifenovir, Ribavirin and Sofosbuvir as potential cures, and all of that are present process trials for COVID-19. “This indicates that the computational model and the state of clinical practice are in sync. However, since the coronavirus is known to mutate quickly, the antiviral drugs have to evolve as well. In such cases, the AI model can help clinicians in selecting only a few effective ones to treat the mutated version,” Majumdar says. His workforce has shared their findings with clinicians and docs at IPGME&R for medical trials and hopes to enhance the computational mannequin by utilizing deep studying strategies and fascinating genetic engineering consultants to grasp the “biology” behind COVID-19.
Application and analysis prospects
“The AI computational model calls for a multidisciplinary approach involving data science, bioinformatics, chemistry, biotechnology etc, for disease diagnosis and treatment. Owing to the fact that COVID-19 often requires a combination of drugs, the AI model can predict the right set of drugs to be used,” says Michael Gromiha, professor, Department of Biotechnology, IIT-Madras who has been utilizing AI to discover disease-causing mutations.
The AI mannequin, he provides, holds immense prospects for college students of analysis as a result of present increase in knowledge and AI’s numerous functions. They can search careers in company analysis within the pharmaceutical and bioinformatics sector or pursue post-doctoral fellowship in academia ought to the sector fascinate them.